A study of Intravenous or Sub-Cut LY4152199 in Participants with previously treated B-Cell Cancers or Leukaemia

Measuring the safety and efficacy of LY4152199 in participants with previously treated B-Cell cancer or Leukaemia

Main Aims

This study aims to find a safe and tolerable dose of LY4152199 in people with previously treated B-Cell cancers or Leukaemia. It would also like to understand how the drug behaves in the body, so it can establish how much drug is in the blood over time.

This study is due to open to recruitment in December 2025.

Recruitment Criteria

• A confirmed diagnosis of a B-Cell cancer (includes WM) or leukaemia
• Previously treated with systemic therapy

Recruitment status: Not Recruiting

Sponsor: Eli Lilly and Company

Expected to end: 01/03/2029

Phases: Phase 1